What type of study is this?

September 17, 2025Journal of Clinical MedicineOpen Access

Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A

View Full Paper

Ask AI

Bookmark

Acetazolamide increased urine output significantly within 72 hours compared to standard therapy.
A total of 82 patients (39.6%) in the acetazolamide group achieved successful decongestion within 72 hours, closely mirroring standard therapy outcomes.
The trial used a randomized, multicenter approach, involving 416 hospitalized patients with decompensated chronic heart failure.
No significant differences were noted in intensive care duration or overall mortality between both treatment groups.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial assesses acetazolamide's impact on urine output and natriuresis in hospitalized heart failure patients, suggesting potential benefits in treatment.

Cite This Study

Сабиров et al. (2025) studied this question.

synapsesocial.com/papers/68d45b1b31b076d99fa5d74f https://doi.org/10.3390/jcm14186517

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial assesses acetazolamide's impact on urine output and natriuresis in hospitalized heart failure patients, suggesting potential benefits in treatment.

Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A

Key Points

Discussion

Implication

Cite This Study

Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider